Washington DC, May 15, 2025 – Mayapada Healthcare attended the DIA (Drug Information Association) 2025 Annual Global Meeting in Washington DC, reinforcing its commitment to advancing clinical trials in Indonesia. 

At this global event, there were 4,000+ attendees and 600+ speakers from pharmaceutical, biotech, and healthcare leaders of 50 countries gathered to shaped future of healthcare through drug development and regulatory updates.  

Through this event, Mayapada highlighted Indonesia’s readiness as a destination for clinical research and invited global sponsors, industries as well as CROs to explore partnerships in the country.

This includes inviting the global leaders to learn updates and growing capabilities on Indonesia’s clinical trial ecosystem through Indonesia Town Hall which was successfully held on June 18, 2025.  

Chief Medical Officer of Mayapada Healthcare, dr. Dini Handayani, MARS, FISQua, FIPC emphasized, “Mayapada is committed in promoting Indonesia’s clinical trial capabilities locally and globally as well as engaging with global leaders, Sponsor and CROs. By improving the visibility and strengthening our clinical trial ecosystem, we are taking a part in Indonesia’s journey toward becoming a preferred destination for global clinical trials, providing access to new treatment to our patients faster and easier.”  

The session fostered lively discussions on how Indonesia can further strengthen its clinical trial ecosystem as well as marking a pivotal moment in Indonesia’s journey toward becoming a preferred destination for global clinical trials. 

We extend our deepest gratitude to all attendees, speakers, and partners who contributed to this milestone. The connections made at DIA 2025 will pave the way for future collaborations, innovative trials, and improved healthcare outcomes in Indonesia and beyond and Mayapada Hospital stands in the advancement of Indonesia clinical trials and beyond. 

Click “Research & Innovation” to learn more about our clinical trials.

tags :